0000000000608918

AUTHOR

Mona Munteanu

0000-0003-4517-2757

showing 4 related works from this author

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin…

2011

Background & Aims EPIC-3 is a prospective, international study that has demonstrated the efficacy of PEG-IFN alfa-2b plus weight-based ribavirin in patients with chronic hepatitis C and significant fibrosis who previously failed any interferon–alfa/ribavirin therapy. The aim of the present study was to assess FibroTest (FT), a validated non-invasive marker of fibrosis in treatment-naive patients, as a possible alternative to biopsy as the baseline predictor of subsequent early virologic (EVR) and sustained virologic response (SVR) in previously treated patients. Methods Of 2312 patients enrolled, 1459 had an available baseline FT, biopsy, and complete data. Uni- (UV) and multi-variable (MV)…

education.field_of_studymedicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industryFibroTestRibavirinPopulationvirus diseasesAlpha interferonHepatitis Cmedicine.diseaseGastroenterologydigestive system diseaseschemistry.chemical_compoundchemistryInternal medicineImmunologyBiopsyMedicinebusinesseducationViral loadInterferon alfamedicine.drugJournal of Hepatology
researchProduct

Consequences of Extended Spectrum Beta-Lactamase-Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Li…

2020

Infections in patients with cirrhosis are associated with liver-related complications (LRCs), especially in patients awaiting liver transplantation (LT). The aim of this study was to evaluate the impact of methicillin-resistant Staphylococcus aureus (MRSA) and extended spectrum beta-lactamase colonization on infections and LRCs for patients on the wait list and on infections after LT. We retrospectively included 250 of 483 patients with cirrhosis who were placed on the wait list for LT from December 2015 to January 2018. These patients were screened for MRSA or extended spectrum beta-lactamase–producing Enterobacteriaceae (ESBLE) at the time of wait-list placement and after LT. Of the patie…

MaleMethicillin-Resistant Staphylococcus aureusmedicine.medical_specialtyCirrhosismedicine.medical_treatmentESBLELiver transplantationmedicine.disease_causeSeverity of Illness Indexbeta-Lactamasesbeta-LactamaseEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicineEnterobacteriaceaeRetrospective StudieRisk FactorsInternal medicineSeverity of illnessMedicineHumansAgedRetrospective Studies0303 health sciencesTransplantation[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyHepatology030306 microbiologybusiness.industryRisk FactorcirrhosisEnterobacteriaceae InfectionsRetrospective cohort studyMiddle Agedmedicine.diseaseEnterobacteriaceae InfectionMethicillin-resistant Staphylococcus aureus3. Good healthLiver TransplantationCarriageCohort030211 gastroenterology & hepatologySurgeryfecal carriageFemalebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyReferences
researchProduct

Corrigendum to: “FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa…

2013

medicine.medical_specialtyHepatologyFibroTestbusiness.industryRibavirinIndependent predictorGastroenterologyPegylated interferon alfa-2bchemistry.chemical_compoundChronic hepatitischemistryVirologic responseInternal medicinemedicinebusinessJournal of Hepatology
researchProduct

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin…

2010

EPIC-3 is a prospective, international study that has demonstrated the efficacy of PEG-IFN alfa-2b plus weight-based ribavirin in patients with chronic hepatitis C and significant fibrosis who previously failed any interferon-alfa/ribavirin therapy. The aim of the present study was to assess FibroTest (FT), a validated non-invasive marker of fibrosis in treatment-naive patients, as a possible alternative to biopsy as the baseline predictor of subsequent early virologic (EVR) and sustained virologic response (SVR) in previously treated patients.Of 2312 patients enrolled, 1459 had an available baseline FT, biopsy, and complete data. Uni- (UV) and multi-variable (MV) analyses were performed us…

AdultLiver CirrhosisMaleBiopsyFibrotestInterferon-alphaAlanine TransaminaseHepatitis C ChronicInterferon alpha-2Middle AgedPrognosisRecombinant ProteinsPolyethylene GlycolsFatty LiverRibavirinHumansDrug Therapy CombinationFemaleProspective Studies
researchProduct